Galmed Pharmaceuticals - GLMD Stock Forecast, Price & News

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Maxim Group lowered Galmed Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, August 8th. Cantor Fitzgerald downgraded Galmed Pharmaceuticals from an "overweight" rating to a "neutral" rating in a report on Thursday, August 4th. Raymond James lowered Galmed Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Wednesday, May 18th. Canaccord Genuity Group lowered shares of Galmed Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, August 8th. Finally, StockNews.com assumed coverage on shares of Galmed Pharmaceuticals in a report on Wednesday. They set a "sell" rating on the stock. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $5.00.

Galmed Pharmaceuticals Stock Down 3.5 %

Shares of GLMD opened at $0.45 on Friday. The company has a current ratio of 8.48, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The firm has a market cap of $11.38 million, a P/E ratio of -0.46 and a beta of 1.34. The stock's 50 day moving average is $0.53 and its two-hundred day moving average is $1.02. Galmed Pharmaceuticals has a 12 month low of $0.38 and a 12 month high of $3.39.

Galmed Pharmaceuticals (NASDAQ:GLMD - Get Rating) last released its quarterly earnings results on Tuesday, May 17th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.09. Analysts predict that Galmed Pharmaceuticals will post -0.69 earnings per share for the current fiscal year.